Abaxis licenses lyophilization technology to bioMerieux

By Elaine Rigoli

Tampa, Fla., March 21 - Abaxis, Inc. said Tuesday it has agreed to license a portion of its patent portfolio covering lyophilization technology to bioMerieux SA.

"Our Orbos lyophilization technology, through the freeze-drying of reagents in small quantities, enables efficient manufacturing of reagents in a convenient and stable format. This license with bioMerieux once again shows that our Orbos technology is quickly becoming a standard format for reagent utilization in molecular diagnostics," said Kenneth Aron, Abaxis vice president of research and development, in a statement.

Abaxis now has several major companies using its Orbos lyophilization technology, according to a company news release.

Abaxis expects further licensing in the fields of molecular diagnostics and environmental monitoring, the release said.

bioMerieux specializes in in-vitro diagnostics for medical and industrial applications. The company is based in I'Etoile, France.

Abaxis develops, manufactures and markets portable blood analysis systems for use in any veterinary or human patient-care setting to provide clinicians with rapid blood constituent measurements. The company is based in Union City, Calif.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.